Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 227 results for "Mk 5172"

Merck's Acquisition Of Idenix Pharmaceuticals Is An Admission Of Inferiority To Sovaldi Regimens
Seeking Alpha

Merck's Acquisition Of Idenix Pharmaceuticals Is An Admission ...

Summary MRK's decision to risk $3.85B of shareholder capital for IDIX "Nuc" assets was driven by its revelation that MK-5172+MK-8742 regimens will require a "Nuc" for activity in GT 2/3. It is an admission by MRK that its MK-5172+MK-8742 combo is ... Seeking Alpha, 1 month ago
Merck to Acquire Idenix American Pharmaceutical Outsourcing, 1 month ago

Pharmacokinetics of Hepatitis C Virus Protease Inhibitor MK-5172 in Volunteers With Mild and Moderate Hepatic Impairment

Reported by Jules Levin 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014 L Caro1, WW Yeh1, M Ho1, N Uemura1, Z Guo1, J Talaty1, C Reitmann1, IP Fraser1, A Testro2, P Angus2, T ...
 National AIDS Treatment Advocacy Project2 months ago The 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy  National AIDS Treatment Advocacy Project1 month ago

Why Merck Is Heading To $65

Summary Management has not lost focus. Merck has a plan to attack and grow its share in immuno-oncologyand entering/dominating the hepatitis C (HCV) and vaccines market. Management continues to offset the near-term weakness with growth in ...
 Seeking Alpha3 hours ago Merck Buys Idenix -- Could Inovio or MannKind Be Next?: StockTwits  TheStreet.com1 month ago

Systematic literature analysis and review of targeted preventive measures to limit healthcare-associated infections by meticillin-resistant Staphylococcus aureus

Report for action from England's chief medical officer on reducing healthcare associated infection in England Letter to the Editor: Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels: are dromedary camels a reservoir for ...
 Eurosurveillance3 days ago
University of Texas

Awards for April, May, and June 2014

Federal Awards Abbara, Suhny, Massachusetts Genl Hosp/NIH, Inflammatory Mechanisms and Treatment Strategies for Atherosclerosis in HIV, $9,677; Ahmad, Zahid, NIH, Molecular Basis of Autosomal Dominant Hypercholesterolemia in a Multiethnic Cohort, ...
 University of Texas4 days ago

Pink Sheet - Proving Ground For Breakthrough Status Coming With Impending User Fee Goals

Novel drug and biologic applications with user fee goals in 2014's second half cluster around infectious disease notably hepatitis C, with three breakthrough drugs pending, antibiotics and meningitis B vaccines (also designated breakthroughs) and ...
 Friends of Cancer Research5 days ago

Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight

/PRNewswire/ -- has added a new market research report: Approval of Gilead's once daily oral ...
 CEOWorld Magazine1 week ago Why Did Merck Pay Such A Huge Premium For Idenix  Trefis1 month ago AAPL, GWPH, FDO Among Hot Stocks on the Move Today By Diane Alter  Tamar Securities1 month ago Merck to Acquire Idenix  CEOWorld Magazine1 month ago
Motley Fool

1 Drug More Important to Gilead Than Sovaldi

Gilead 's ( NASDAQ: GILD ) Sovaldi roared out of the gate following its FDA approval in December. Sales of the drug totaled more than $2.2 billion in its first quarter on the market, making it the fastest drug to ever reach billion-dollar ...
 Motley Fool2 weeks ago Can Anyone Dethrone Gilead?  Motley Fool1 month ago

ISRO Units in Dist have Reason to be Happy

THIRUVANANTHAPURAM: With big missions lined up for the immediate future, units of the Indian Space Research Organisation (ISRO) in Thiruvananthapuram have received ample attention in the Union Budget presented on Thursday. The Vikram Sarabhai ...
 New Indian Express2 weeks ago

Merck makes big HCV move with Idenix deal

WHITEHOUSE STATION, N.J.—With Gilead's Sovaldi dominating the hepatitis C virus (HCV) treatment news, both because of its effectiveness and being the best drug launch ever with $2.3 billion in sales in its first quarter, Merck has decided to make ...
 Drug Discovery News2 weeks ago FDA HCV Submissions / HCV Update  National AIDS Treatment Advocacy Project1 month ago Merck to Acquire Idenix  PharmTech.com1 month ago Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV  Yahoo! Finance1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less